These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21255398)

  • 21. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
    O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
    Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
    Gondo N; Sakai Y; Zhang Z; Hato Y; Kuzushima K; Phimsen S; Kawashima Y; Kuroda M; Suzuki M; Okada S; Iwata H; Toyama T; Rezano A; Kuwahara K
    Lab Invest; 2021 Aug; 101(8):1048-1059. PubMed ID: 34031538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression.
    Chan P; Möller A; Liu MC; Sceneay JE; Wong CS; Waddell N; Huang KT; Dobrovic A; Millar EK; O'Toole SA; McNeil CM; Sutherland RL; Bowtell DD; Fox SB
    Breast Cancer Res; 2011 Feb; 13(1):R19. PubMed ID: 21306611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
    Spears M; Taylor KJ; Munro AF; Cunningham CA; Mallon EA; Twelves CJ; Cameron DA; Thomas J; Bartlett JM
    Breast Cancer Res Treat; 2012 Apr; 132(2):463-70. PubMed ID: 21638049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
    Tishchenko I; Milioli HH; Riveros C; Moscato P
    PLoS One; 2016; 11(6):e0158259. PubMed ID: 27341628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease.
    Gong DH; Fan L; Chen HY; Ding KF; Yu KD
    Oncotarget; 2016 May; 7(19):28570-8. PubMed ID: 27086913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
    Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cohesin is required for activation of MYC by estradiol.
    McEwan MV; Eccles MR; Horsfield JA
    PLoS One; 2012; 7(11):e49160. PubMed ID: 23145106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
    Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.